TNF and rheumatoid arthritis: A more recent double-blind placebo-controlled clinical study (DANCER) confirmed that in RA patients who were refractory to conventional therapies and the TNFα inhibitors, rituximab treatment (2 doses of 1000 mg or 500 mg) led to significantly higher rates of ACR responses and EULAR moderate / good responses when compared to placebo infusion [9].